MBX Biosciences (MBX) Research & Development (2023 - 2026)
MBX Biosciences (MBX) reported Research & Development of $1.3 million for Q1 2026, down 94.32% on a YoY basis from $22.4 million in Q1 2025, and down 93.56% sequentially from $19.8 million in Q4 2025.
MBX Biosciences (MBX) Research & Development (2023 - 2026) Analysis & Trends
MBX Biosciences (MBX) has 4 years of Research & Development data on file, last reported at $1.3 million in Q1 2026.
- For the quarter ending Q1 2026, Research & Development fell 94.32% year-over-year to $1.3 million; the trailing twelve-month figure through Mar 2026 stood at $58.0 million (up 44.77% YoY), and the FY2025 full-year result was $79.2 million, up 5802.98% from the prior year.
- Research & Development retreated to $1.3 million in Q1 2026, from $19.8 million in the prior quarter.
- In the past five years, Research & Development ranged from a high of $22.4 million in Q1 2025 to a low of -$18.6 million in Q4 2023.
- A 4-year average of $9.1 million and a median of $11.0 million in 2024 frame the typical range for Research & Development.
- Across the five-year window, Research & Development soared 4850.84% in 2025 and sank 94.32% in 2026, its largest moves.
- Tracing MBX's Research & Development over 4 years: stood at -$18.6 million in 2023, then soared by 103.08% to $572000.0 in 2024, then soared by 3354.37% to $19.8 million in 2025, then plunged by 93.56% to $1.3 million in 2026.
- Business Quant data shows MBX's Research & Development at $1.3 million in Q1 2026, $19.8 million in Q4 2025, and $19.3 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - | -17.94 Mn |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | 1.46 Mn |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn | 541.22 Mn |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn | 961.60 Mn |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn | 1.54 Bn |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - | 15.66 Mn |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn | -443.00 Mn |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - | 343.97 Mn |
| 10 | MBX Biosciences | 2.89 Bn | 2.89 Bn | - | 1.27 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 1.27 Mn |
| Dec 31, 2025 | 19.76 Mn |
| Sep 30, 2025 | 19.27 Mn |
| Jun 30, 2025 | 17.72 Mn |
| Mar 31, 2025 | 22.41 Mn |
| Dec 31, 2024 | 572,000.00 |
| Sep 30, 2024 | 16.75 Mn |
| Jun 30, 2024 | 358,000.00 |
| Mar 31, 2024 | 11.05 Mn |
| Dec 31, 2023 | -18.59 Mn |
| Sep 30, 2023 | 9.07 Mn |